首页> Leukemia & lymphoma> The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

导出 LinkOut

翻译打印收藏纠错

第一作者： Matthew D,Seftel

第一单位： a Department of Medical Oncology and Hematology , CancerCare Manitoba and University of Manitoba , Winnipeg , MB , Canada.

作者： Matthew D,Seftel ^[1] ; John,Kuruvilla ^[2] ; Tom,Kouroukis ^[3] ; Versha,Banerji ^[1] ; Graeme,Fraser ^[3] ; Michael,Crump ^[2] ; Rajat,Kumar ^[1] ; Haji I,Chalchal ^[4] ; Muhammad,Salim ^[4] ; Rob C,Laister ^[2] ; Susan,Crocker ^[5] ; Spencer B,Gibson ^[6] ; Marcia,Toguchi ^[7] ; John F,Lyons ^[7] ; Hao,Xu ^[8] ; Jean,Powers ^[8] ; Joana,Sederias ^[8] ; Lesley,Seymour ^[8] ; Annette E,Hay ^[9]

作者单位： a Department of Medical Oncology and Hematology , CancerCare Manitoba and University of Manitoba , Winnipeg , MB , Canada. ^[1] b Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre and University of Toronto , Toronto , ON , Canada. ^[2] c Department of Oncology , Juravinski Cancer Centre and McMaster University , Hamilton , ON , Canada. ^[3] d Department of Hematology , Allan Blair Cancer Centre , Regina , SK , Canada.;e University of Saskatchewan , Saskatchewan , SK , Canada. ^[4] f Department of Pathology and Molecular Medicine , Queen's University , Kingston , ON , Canada. ^[5] g Research Institute of Oncology and Hematology, CancerCare Manitoba and Department of Biochemistry , University of Manitoba , Winnipeg , MB , Canada. ^[6] h Astex Pharmaceuticals , Cambridge , UK. ^[7] i Canadian Cancer Trials Group , Queen's University , Kingston , ON , Canada. ^[8] i Canadian Cancer Trials Group , Queen's University , Kingston , ON , Canada.;j Department of Medicine , Queen's University , Kingston , ON , Canada. ^[9]

关键词 Chronic lymphocytic leukemia cyclin-dependent kinase inhibitors mantle cell lymphoma